Since HPIP is overexpressed in CRC patients and promotes tumor growth in vivo, inhibition of ERK1/2 and AKT or inhibition of HPIP may be useful strategies for the treatment of HPIP-overexpressing CRC patients. Here, PBXIP1 is linked to colorectal carcinoma.